First 100 Days in Office : The Impact of the Trump presidency on the Canadian Pharmaceutical Environment

To mark our first PharmAlliance special session, we are joined by the expertise of the Honourable Raymond Chrétien and esteemed Howard Sklamberg to discuss the potential impacts of the second Trump presidency on the Canadian Pharmaceutical environment. Fasken’s own Me. Chrétien will enlighten us as a previous federal public servant and through his extensive experience with the business community, international financing agencies, government affairs and international negotiations and trade agreements. Mr. Sklamberg will be joining us from the U.S. law firm, Arnold & Porter, providing us with perspectives on U.S. drug law and policy, as he previously held many senior roles at the Food and Drug Administration. Moderated by Me. Robert Quesnel, this presentation will center the considerations of in-house pharmaceutical counsel amongst the shifting landscape.

Also on the agenda is a review of hot topics in the Canadian legal and regulatory landscape, and a demonstration of the newly launched PharmAlliance platform which features our ever-expanding toolkit and access to other key resources.